
    
      Household members were contacted by telephone and provided consent forms via E-mail
      electronic signatures. Randomization was 2:1 to HCQ 200 mg BID or observation for 10 days
      with total follow-up of 14 days. COVID status was determined by home saliva PCR assay on days
      1 and 14. Study drug was shipped to participants. Data of daily symptoms and 6-lead ECGs
      using a smartphone KardiaMobileÂ® 6L application were collected.
    
  